TY - JOUR
T1 - MicroRNAs in Chronic Kidney Disease
T2 - Four Candidates for Clinical Application
AU - Peters, Linsey J. F.
AU - Floege, Juergen
AU - Biessen, Erik A. L.
AU - Jankowski, Joachim
AU - van der Vorst, Emiel P. C.
N1 - Funding Information:
Funding: The authors’ research is supported by a grant from the Interdisciplinary Center for Clinical Research within the faculty of Medicine at the RWTH Aachen University, the DZHK (German Centre for Cardiovascular Research) and the BMBF (German Ministry of Education and Research), and NWO-ZonMw Veni (91619053) to E.P.C.v.d.V and by the DFG (SFB/TRR219 TP C-04, S-03) to J.J. and by the DFG (SFB/TRR219 TP C-01, M-01) to J.F.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/9/2
Y1 - 2020/9/2
N2 - There are still major challenges regarding the early diagnosis and treatment of chronic kidney disease (CKD), which is in part due to the fact that its pathophysiology is very complex and not clarified in detail. The diagnosis of CKD commonly is made after kidney damage has occurred. This highlights the need for better mechanistic insight into CKD as well as improved clinical tools for both diagnosis and treatment. In the last decade, many studies have focused on microRNAs (miRs) as novel diagnostic tools or clinical targets. MiRs are small non-coding RNA molecules that are involved in post-transcriptional gene regulation and many have been studied in CKD. A wide array of pre-clinical and clinical studies have highlighted the potential role for miRs in the pathogenesis of hypertensive nephropathy, diabetic nephropathy, glomerulonephritis, kidney tubulointerstitial fibrosis, and some of the associated cardiovascular complications. In this review, we will provide an overview of the miRs studied in CKD, especially highlighting miR-103a-3p, miR-192-5p, the miR-29 family and miR-21-5p as these have the greatest potential to result in novel therapeutic and diagnostic strategies.
AB - There are still major challenges regarding the early diagnosis and treatment of chronic kidney disease (CKD), which is in part due to the fact that its pathophysiology is very complex and not clarified in detail. The diagnosis of CKD commonly is made after kidney damage has occurred. This highlights the need for better mechanistic insight into CKD as well as improved clinical tools for both diagnosis and treatment. In the last decade, many studies have focused on microRNAs (miRs) as novel diagnostic tools or clinical targets. MiRs are small non-coding RNA molecules that are involved in post-transcriptional gene regulation and many have been studied in CKD. A wide array of pre-clinical and clinical studies have highlighted the potential role for miRs in the pathogenesis of hypertensive nephropathy, diabetic nephropathy, glomerulonephritis, kidney tubulointerstitial fibrosis, and some of the associated cardiovascular complications. In this review, we will provide an overview of the miRs studied in CKD, especially highlighting miR-103a-3p, miR-192-5p, the miR-29 family and miR-21-5p as these have the greatest potential to result in novel therapeutic and diagnostic strategies.
KW - MicroRNAs
KW - kidney fibrosis
KW - chronic kidney disease
KW - clinical application
KW - PROMOTES RENAL FIBROSIS
KW - DIABETIC-NEPHROPATHY
KW - DOWN-REGULATION
KW - COLLAGEN EXPRESSION
KW - HIGH GLUCOSE
KW - MESENCHYMAL TRANSITION
KW - CARDIORENAL SYNDROME
KW - ANGIOTENSIN-II
KW - MOUSE MODEL
KW - AKT KINASE
U2 - 10.3390/ijms21186547
DO - 10.3390/ijms21186547
M3 - (Systematic) Review article
C2 - 32906849
SN - 1661-6596
VL - 21
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 18
M1 - 6547
ER -